[Clinical experience with the use of infliximab in 44 patients with Crohn's disease].
To evaluate the efficacy of infliximab in the treatment of patients with active Crohn's disease or with fistulas. Forty four patients with Crohn's disease, resistant to conventional therapies, were treated with 5 mg/kg endovenous infliximab infusions. Thirty of them (68.2%) improved, with important reduction on disease activity levels, measured by the CDAI (Crohn's Disease Activity Index). Eight (57.1%) of 14 patients with fistulas also showed good results, with closure or important reduction in their flow. The drug was well tolerated in all cases. The use of infliximab in these cases seems to be a good therapeutic option, with low rates of side effects.